Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

IPN60300

PreclinicalBiologic

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced Solid TumorRecruiting

Locally Advanced Solid TumorPreclinical

Recruiting

Timeline

Expected Milestones

Q4 2028

PreclinicalRecruiting

Locally Advanced Solid Tumor

NCT07213817

Clinical

Trials by Indication[1]

Locally Advanced Solid Tumor1 trial

An Open-Label, Phase I/II First-in-Human, Dose Escalation, Dose Optimisation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 as Single Agent in Adult Participants With Locally Advanced or Metastatic Solid Tumours.

Recruiting· Ipsen logo

Ipsen·Preclinical·NCT07213817·114 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IPN60300. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IPN60300 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IPN60300. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ipsen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: Ipsen

Related News